Once-daily deucrictibant XR reduced hereditary angioedema attacks by 83% across the Phase 3 CHAPTER-3 population, giving Pharvaris a potential oral prophylaxis product alongside its separately developed immediate-release rescue formulation.
KalVista's sebetralstat pediatric trial data heads to Madrid. What it means for the HAE on-demand market and a 2026 FDA filing. Read the analysis.
Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a Shanghai-based clinical-stage RNA interference therapeutics company, has received Fast Track Designation from the U.S. Food and Drug Administration for BW-20805, its investigational small interfering RNA therapy targeting prekallikrein for the prevention of hereditary angioedema attacks. The designation comes as the company runs a global Phase II open-label study